Pharmalot By Ed Silverman Mylan refuses to testify at Senate hearing about EpiPen rebates to Medicaid
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: FTC is ‘aware’ of concerns over possible Mylan antitrust violations
Pharmalot By Ed Silverman Lawmakers call for FTC probe into potential antitrust violations in EpiPen school program
Pharmalot By Ed Silverman Hospitals are itching for a share of the Mylan settlement over Medicaid rebates
Pharmalot By Ed Silverman West Virginia AG vows to reject ‘woefully deficient’ Mylan deal with the feds
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Drug stocks hurt by fears that price hikes are abating
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Pfizer will sell a biosimilar version of Remicade next month
The Pharmalot View By Ed Silverman Health officials should reject latest gambit by EpiPen maker to feed at the public trough
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Chicago can proceed with lawsuit against opioid drug makers
Pharmalot By Ed Silverman Feds slam Mylan for misclassifying EpiPen, with ‘financial consequences’ to Medicaid
First Opinion By James R. Baker Jr. EpiPen pricing controversy reflects larger issues in pharma industry
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Most Californians support proposed law to limit drug prices
The Pharmalot View By Ed Silverman Behind the grandstanding, Congress may have taken a key step to clarifying drug prices
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Mylan’s parent bloggers feel jilted thanks to price hikes
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Congress probes FDA’s Office of Criminal Investigations